Latest filing published 22 Sept 2026 for SCYNEXIS INC.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -37.0%Entry US$4.87 · Close at T+365 US$3.07
- +2.2%Entry US$74.00 · Close at T+365 US$75.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Steven Keith Burke: trading record in brief
Steven Keith Burke is a declared insider at 3 companies (senior executive); the most frequent names are Akebia Therapeutics, Inc., Protara Therapeutics, Inc. and Scynexis Inc. The record holds 57 filings, for trades running from 30 June 2015 to 18 September 2026.
Both buying and selling appear: 2 purchases worth €106k, against 22 sales worth €421k. Sales outweigh purchases by €314k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 16 share grants and 2 option exercises. 2026 to date brings no purchases and 3 sales.
Most recently, on 22 September 2026, the filings show a share grant in Scynexis Inc. The last insider purchase was made public on 22 November 2019, 2,543 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Steven Keith Burke
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,750 shares0Common StockSEC:0001193125-26-397873:0
- 25,375 shares@ US$1.395.9% of flowCommon StockSEC:0001619834-26-000002:1
- 20,701 shares@ US$1.394.8% of flowCommon StockSEC:0001619834-26-000002:2
- 21,582 shares@ US$1.3914.1% of flowCommon StockSEC:0001619834-26-000002:0
- 204,000 shares0Common StockSEC:0001619834-26-000001:0
- 7,144 shares@ US$1.837.0% of flowCommon StockSEC:0001562180-25-001997:0
- 23,270 shares@ US$2.109.4% of flowCommon StockSEC:0001562180-25-000916:1
- 27,236 shares@ US$2.1011.0% of flowCommon StockSEC:0001562180-25-000916:2
- 194,900 shares0Common StockSEC:0001562180-25-000916:0
- 27,000 shares@ US$1.1516.0% of flowCommon StockSEC:0001562180-24-003948:0
- 7,169 shares@ US$1.585.8% of flowCommon StockSEC:0001562180-24-002020:0
- 8,367 shares@ US$1.526.5% of flowCommon StockSEC:0001562180-24-001993:0
- 24,311 shares@ US$1.687.4% of flowCommon StockSEC:0001562180-24-000970:1
- 202,200 shares0Common StockSEC:0001562180-24-000970:0
- 63,567 shares@ US$1.06834.8% of flowCommon StockSEC:0001562180-23-004254:0
- 6,400 shares@ US$0.87751.0% of flowCommon StockSEC:0001562180-23-002199:1
- 1,110 shares@ US$0.87750.2% of flowCommon StockSEC:0001562180-23-002199:2
- 6,613 shares@ US$0.87753.1% of flowCommon StockSEC:0001562180-23-002199:0
- 7,539 shares@ US$0.81323.2% of flowCommon StockSEC:0001562180-23-002040:0
- 196,200 shares0Common StockSEC:0001562180-23-000830:0
- 1,147 shares@ US$0.36250.2% of flowCommon StockSEC:0001562180-22-006402:0
- 200,000 shares0Common StockSEC:0001562180-22-004031:0
- 6,556 shares@ US$2.172.5% of flowCommon StockSEC:0001562180-22-002165:2
- 1,100 shares@ US$2.170.4% of flowCommon StockSEC:0001562180-22-002165:3
- 60,000 shares0Common StockSEC:0001562180-22-002165:1
25 of 57 declarations
